EHLS:NSD- (USD)

ETF | Others |

Last Closing

USD 20.1805

Change

-0.22 (-1.06)%

Market Cap

N/A

Volume

6.60K
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
QQQM Invesco NASDAQ 100 ETF

-1.08 (-0.54%)

USD 29.04B
ACWI iShares MSCI ACWI ETF

-0.22 (-0.20%)

USD 18.71B
IBIT iShares Bitcoin Trust

-0.84 (-2.40%)

USD 17.74B
CGABL The Carlyle Group Inc. 4.625% ..

-0.08 (-0.46%)

USD 16.14B
JEPQ JPMorgan Nasdaq Equity Premium..

-0.06 (-0.11%)

USD 14.61B
TBIL Rbb Fund Inc - Us Treasury 3 M..

+0.01 (+0.02%)

USD 3.07B
IBTE iShares iBonds Dec 2024 Term T..

+0.01 (+0.04%)

USD 2.79B
IBTF iShares iBonds Dec 2025 Term T..

+0.02 (+0.06%)

USD 2.33B
NVDL GraniteShares 2x Long NVDA Dai..

-0.59 (-0.84%)

USD 2.05B
USCL iShares Climate Conscious & Tr..

-0.19 (-0.29%)

USD 2.01B

ETFs Containing EHLS

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike